{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T19:22:22Z","timestamp":1775848942860,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.pharep.2016.09.001","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T12:50:26Z","timestamp":1473425426000},"page":"1339-1344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Does valproate therapy in epileptic patients contribute to changing atherosclerosis risk factors? The role of lipids and free fatty acids"],"prefix":"10.1007","volume":"68","author":[{"given":"El\u017cbieta","family":"P\u0142onka-P\u00f3\u0142torak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Zagrodzki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jadwiga","family":"Kryczyk-Kozio\u0142","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuomas","family":"Westermarck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pekka","family":"Kaipainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Kaski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faik","family":"Atroshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"4","key":"10.1016\/j.pharep.2016.09.001_bib0005","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"A practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.pharep.2016.09.001_bib0010","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/j.1528-1167.2009.02024.x","article-title":"Long-term antiepileptic drug therapy contributes to the acceleration of atherosclerosis","volume":"50","author":"Tan","year":"2009","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.pharep.2016.09.001_bib0015","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1528-1167.2011.03316.x","article-title":"Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis","volume":"53","author":"Chuang","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharep.2016.09.001_bib0020","first-page":"1","article-title":"Fatty liver in adults receiving antiepileptic medications: relationship to the metabolic risks","volume":"8","author":"Hamed","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.pharep.2016.09.001_bib0025","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1111\/epi.12338","article-title":"Effects of new antiepileptic drugs on circulatory markers for vascular risk in patients with newly diagnosed epilepsy","volume":"54","author":"Kim","year":"2013","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.pharep.2016.09.001_bib0030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1734-1140(11)70497-2","article-title":"Basic mechanisms of antiepileptic drugs and their pharmacokinetic\/pharmacodynamic interactions: an update","volume":"63","author":"Laso\u0144","year":"2011","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.pharep.2016.09.001_bib0035","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/j.1528-1157.1999.tb02034.x","article-title":"Modulation of sodium currents in rat CA1 neurons by carbamazepine and valproate after kindling epileptogenesis","volume":"40","author":"Vreugdenhil","year":"1999","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.pharep.2016.09.001_bib0040","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1053\/meta.2002.34708","article-title":"Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy","volume":"51","author":"Luef","year":"2002","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.pharep.2016.09.001_bib0045","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1463-1326.2011.01453.x","article-title":"Brain glucose sensing and neural regulation of insulin and glucagon secretion","volume":"13","author":"Thorens","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"1-2","key":"10.1016\/j.pharep.2016.09.001_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2013.08.016","article-title":"Metabolic and endocrine effects of valproic acid chronic treatment","volume":"107","author":"Belcastro","year":"2013","journal-title":"Epilepsy Res"},{"issue":"2","key":"10.1016\/j.pharep.2016.09.001_bib0055","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","article-title":"Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review","volume":"31","author":"Silva","year":"2008","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"10.1016\/j.pharep.2016.09.001_bib0060","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0920-1211(93)90040-E","article-title":"Valproate and palmitate binding to serum albumin in valproate-treated patients. Relation to obesity","volume":"16","author":"Vorum","year":"1993","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.pharep.2016.09.001_bib0065","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2337\/diabetes.51.1.7","article-title":"Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes","volume":"51","author":"McGarry","year":"2002","journal-title":"Diabetes"},{"issue":"1-2","key":"10.1016\/j.pharep.2016.09.001_bib0070","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0920-1211(03)00091-3","article-title":"Valproic acid modulates islet cell insulin secretion: a possible mechanism of weight gain in epilepsy patients","volume":"55","author":"Luef","year":"2003","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.pharep.2016.09.001_bib0075","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.seizure.2013.07.007","article-title":"The effects of topiramate and valproate therapy on insulin, c-peptide, leptin, neuropeptide Y, adiponectin, visfatin, and resistin levels in children with epilepsy","volume":"22","author":"Sonmez","year":"2013","journal-title":"Seizure"},{"issue":"5","key":"10.1016\/j.pharep.2016.09.001_bib0080","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1111\/j.1467-789X.2010.00800.x","article-title":"Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications","volume":"12","author":"Verrotti","year":"2011","journal-title":"Obes Rev"},{"issue":"6","key":"10.1016\/j.pharep.2016.09.001_bib0085","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1038\/emm.2014.38","article-title":"CD36, a scavenger receptor implicated in atherosclerosis","volume":"46","author":"Park","year":"2014","journal-title":"Exp Mol Med"},{"issue":"2-3","key":"10.1016\/j.pharep.2016.09.001_bib0090","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.eplepsyres.2007.03.010","article-title":"Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy","volume":"74","author":"Hamed","year":"2007","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.pharep.2016.09.001_bib0095","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1007\/s12011-011-9003-3","article-title":"Valproic acid modulates superoxide dismutase, uric acid-independent FRAP and zinc in blood of adult epileptic patients","volume":"143","author":"P\u0142onka-P\u00f3\u0142torak","year":"2011","journal-title":"Biol Trace Elem Res"},{"key":"10.1016\/j.pharep.2016.09.001_bib0100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-2275(20)39633-4","article-title":"Colorimetric determination of free fatty acids in biological fluids","volume":"6","author":"Itaya","year":"1965","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharep.2016.09.001_bib0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0378-4347(00)83435-0","article-title":"Quantitative determination of the fatty acid composition of human serum lipids by high-performance liquid chromatography","volume":"383","author":"Shimomura","year":"1986","journal-title":"J. Chromatogr"},{"issue":"7","key":"10.1016\/j.pharep.2016.09.001_bib0110","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0009-9120(01)00263-6","article-title":"The plasma parameter log (TG\/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL))","volume":"34","author":"Dobi\u00e1sov\u00e1","year":"2001","journal-title":"Clin Biochem"},{"issue":"2","key":"10.1016\/j.pharep.2016.09.001_bib0115","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacl.2010.02.005","article-title":"Atherogenic index of plasma (log10 triglyceride\/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events","volume":"4","author":"Onat","year":"2010","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pharep.2016.09.001_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0021-9150(96)05851-0","article-title":"Lipids, risk factors and ischaemic heart disease","volume":"124","author":"Castelli","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharep.2016.09.001_bib0125","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/bib\/bbl016","article-title":"Partial Least Squares: a versatile tool for the analysis of high-dimensional genomic data","volume":"8","author":"Boulesteix","year":"2007","journal-title":"Brief Bioinform"},{"issue":"12","key":"10.1016\/j.pharep.2016.09.001_bib0130","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/j.0013-9580.2004.17504.x","article-title":"The epidemiology of the comorbidity of epilepsy in the general population","volume":"45","author":"Gaitatzis","year":"2004","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.pharep.2016.09.001_bib0135","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pds.2186","article-title":"Effects of epilepsy and selected antiepileptic drugs on risk of myocardial infarction, stroke, and death in patients with or without previous stroke: a nationwide cohort study","volume":"20","author":"Olesen","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"10.1016\/j.pharep.2016.09.001_bib0140","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/pds.3651","article-title":"Is sodium valproate, an HDAC inhibitor, associated with reduced risk of stroke and myocardial infarction? A nested case-control study","volume":"23","author":"Dregan","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"10.1016\/j.pharep.2016.09.001_bib0145","doi-asserted-by":"crossref","first-page":"e008365","DOI":"10.1136\/bmjopen-2015-008365","article-title":"Antiepileptic drugs and the risk of ischaemic stroke and myocardial infarction: a population-based cohort study","volume":"5","author":"Renoux","year":"2015","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.pharep.2016.09.001_bib0150","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4065\/80.2.219","article-title":"Conditional risk factors for atherosclerosis","volume":"80","author":"Kullo","year":"2005","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.pharep.2016.09.001_bib0155","first-page":"e5","article-title":"Relationship between antiepileptic drugs and biological markers affecting long-term cardiovascular function in children and adolescents","volume":"17","author":"Cheng","year":"2010","journal-title":"Can J Clin Pharmacol"},{"key":"10.1016\/j.pharep.2016.09.001_bib0160","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.eplepsyres.2015.03.002","article-title":"Antiepileptic drug use for treatment of epilepsy and dyslipidemia: systematic review","volume":"113","author":"Vyas","year":"2015","journal-title":"Epilepsy Res"},{"issue":"8","key":"10.1016\/j.pharep.2016.09.001_bib0165","first-page":"HC05","article-title":"Evaluation of effect of antiepileptic drugs on serum lipid profile among young adults with epilepsy in a tertiary care hospital in pondicherry","volume":"8","author":"Manimekalai","year":"2014","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.pharep.2016.09.001_bib0170","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.seizure.2012.06.001","article-title":"Metabolic syndrome among Chinese obese patients with epilepsy on sodium valproate","volume":"21","author":"Fang","year":"2012","journal-title":"Seizure"},{"issue":"6","key":"10.1016\/j.pharep.2016.09.001_bib0175","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.eplepsyres.2014.04.006","article-title":"Vascular function and risk factors in children with epilepsy: associations with sodium valproate and carbamazepine","volume":"108","author":"Keenan","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.pharep.2016.09.001_bib0180","first-page":"MT50","article-title":"The effect of long\u2010term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy","volume":"4","author":"Nikolaos","year":"2004","journal-title":"Med Sci Monit"},{"issue":"1","key":"10.1016\/j.pharep.2016.09.001_bib0185","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4103\/0253-7613.150328","article-title":"Effects of valproate on the carotid artery intima-media thickness in epileptics","volume":"47","author":"Luo","year":"2015","journal-title":"Indian J Pharmacol"},{"issue":"2\u20133","key":"10.1016\/j.pharep.2016.09.001_bib0190","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.eplepsyres.2010.07.011","article-title":"Effects of AEDs on biomarkers in people with epilepsy: CRP, HbA1c and eGFR","volume":"91","author":"Yuen","year":"2010","journal-title":"Epilepsy Res"},{"issue":"5","key":"10.1016\/j.pharep.2016.09.001_bib0195","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jacc.2013.05.016","article-title":"High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?","volume":"62","author":"Yousuf","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.pharep.2016.09.001_bib0200","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3109\/00207454.2014.949704","article-title":"Epilepsy and antiepileptic drugs: risk factors for atherosclerosis","volume":"125","author":"Talaat","year":"2015","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.pharep.2016.09.001_bib0205","series-title":"Fatty Acids in Foods and their Health Implications","first-page":"591","article-title":"The effects of dietary fatty acids on lipid metabolism","author":"Vemuri","year":"2008"},{"issue":"3","key":"10.1016\/j.pharep.2016.09.001_bib0210","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.yebeh.2006.02.008","article-title":"Insulin-related metabolic changes during treatment with valproate in patients with epilepsy","volume":"8","author":"Pylv\u00e4nen","year":"2006","journal-title":"Epilepsy Behav"},{"issue":"5","key":"10.1016\/j.pharep.2016.09.001_bib0215","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1046\/j.1528-1157.2003.09802.x","article-title":"Effects of valproic acid, carbamazepine, and phenobarbitone on the fatty acid composition of erythrocyte membranes in children","volume":"44","author":"K\u00f6nig","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharep.2016.09.001_bib0220","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1056\/NEJM198805123181905","article-title":"Effect of dietary stearic acid on plasma cholesterol and lipoprotein levels","volume":"319","author":"Bonanome","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharep.2016.09.001_bib0225","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1161\/01.ATV.14.4.567","article-title":"Impact of myristic acid versus palmitic acid on serum lipid and lipoprotein levels in healthy women and men","volume":"14","author":"Zock","year":"1994","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.pharep.2016.09.001_bib0230","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3945\/ajcn.2009.27661","article-title":"Cardiovascular disease risk of dietary stearic acid compared with trans, other saturated, and unsaturated fatty acids: a systematic review","volume":"91","author":"Hunter","year":"2010","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"10.1016\/j.pharep.2016.09.001_bib0235","doi-asserted-by":"crossref","first-page":"e0120424","DOI":"10.1371\/journal.pone.0120424","article-title":"Dietary triacylglycerols with palmitic acid in the sn-2 position,modulate levels of N-acylethanolamides in rat tissues","volume":"10","author":"Carta","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pharep.2016.09.001_bib0240","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.neuropharm.2012.11.017","article-title":"Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-\u03b1 receptor activation in a genetic model of absence epilepsy","volume":"69","author":"Citraro","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharep.2016.09.001_bib0245","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jpba.2014.04.009","article-title":"The effect of hyperglycemia on the pharmacokinetics of valproic acid studied by high-performance liquid chromatography with electrochemical detection","volume":"97","author":"Kotani","year":"2014","journal-title":"J Pharm Biomed Anal"},{"issue":"4","key":"10.1016\/j.pharep.2016.09.001_bib0250","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s11940-010-0080-y","article-title":"Antiepileptic drugs and markers of vascular risk","volume":"12","author":"Lopinto-Khoury","year":"2010","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"10.1016\/j.pharep.2016.09.001_bib0255","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1528-1167.2006.00833.x","article-title":"Effects of valproate on acylcarnitines in children with epilepsy using ESI\u2013MS\/MS","volume":"48","author":"Wener","year":"2007","journal-title":"Epilepsia"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114016301384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114016301384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:36:39Z","timestamp":1752611799000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2016.09.001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S1734114016301384"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2016.09.001","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does valproate therapy in epileptic patients contribute to changing atherosclerosis risk factors? The role of lipids and free fatty acids","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2016.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Sp. z o.o. on behalf of Institute of Pharmacology, Polish Academy of Sciences.","name":"copyright","label":"Copyright"}]}}